Rebiotix's Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017
Data Examining RBX2660 Treatment in Relation to "Healthy" Gut Microbiome, Placebo Response Rates in a Meta Analysis and Microbiome Engraftment to be Showcased
ROSEVILLE, Minn., June 1, 2017 /PRNewswire/ -- Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it will present three posters during the American Society for Microbiology's ASM Microbe 2017, being held June 1-5, 2017 in New Orleans. One poster will be part of the general poster sessions, and two will be highlighted as "Poster Talks," where they will be presented orally with an opportunity to take questions from the audience. The posters include data analyses from clinical studies featuring RBX2660, Rebiotix's Phase 3-ready broad spectrum microbiota suspension designed to rehabilitate the human microbiome by delivering live microbes into a patient's intestinal tract to treat disease.
The schedule of Rebiotix-focused presentations at ASM Microbe 2017 is as follows:
| Poster Presentation: |
Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects' Profile |
|
| Investigators |
K. Blount, C. Jones, B. Shannon, S. Carter |
|
| Day & Time |
Saturday, June 3rd, 12:15 PM – 2:15 PM, CT |
|
| Session & Location: |
193-AAID08 – Infection Prevention and Control: Treatment and Prevention |
|
| Poster Talk: |
Meta-analysis of Response Rates Among Placebo-Treated Patients from Five Clinical Trials of Experimental Recurrent Clostridium difficile Therapeutics |
|
| Investigators: |
D. Gerding, C. Jones, K. Blount, B. Shannon |
|
| Day & Time: |
Sunday, June 4th; 1:15 PM – 1:25 PM, CT |
|
| Session & Location: |
Hot News on Epidemiology and Management of C. difficile infection – |
|
| Poster Talk: |
Resetting the Microbial Landscape: Donor Microbiome Engraftment in Patients Treated with RBX2660 for Multi-Recurrent Clostridium difficile Infection |
|
| Investigators: |
A. Ray, C. Jones, B. Shannon, S. Carter |
|
| Day & Time: |
Sunday, June 4th; 1:45 PM – 1:55 PM, CT |
|
| Session & Location: |
Hot News on Epidemiology and Management of C. difficile infection – |
About Rebiotix Inc.
Rebiotix Inc. is a clinical-stage microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its lead drug candidate, RBX2660, expected to enter Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix's clinical pipeline also features RBX7455, a room temperature stable oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff. infection. In addition, Rebiotix is targeting several other disease indications with drug products built on its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Jason Rando
Tiberend Strategic Advisors
212-375-2665
[email protected]
SOURCE Rebiotix Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article